Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Medtronic shuffle: Former Vascular Business President William Hawkins takes over as firm's president & COO May 3. Hawkins' new responsibilities include ensuring robust development of Medtronic's worldwide product lines and geographic operating units. Current CEO Art Collins was the last to occupy the COO position in 2001. Scott Ward supplants Hawkins, taking control of Medtronic's DES development program. The firm expects to present 12-month Endeavor I DES data at the Paris Course on Revascularization meeting May 25-28. Separately, Ward, who previously led Medtronic's neurological and diabetes businesses, says that Medtronic "is positioned to launch the world's first artificial pancreas in the next 12-18 months"...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT020203

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel